Dialogues

Oct 25, 2024, 12:44

ASCO24 Updates: Felix Blanc-Durand on Clear Cell Endometrial Cancer Findings

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Felix Blanc-Durand from Gustave-Roussy, France, and National University Hospital in Singapore, shared insights on ‘Unveiling the unique identity of clear-cell endometrial cancer (CCEC): A comprehensive comparative analysis with ovarian counterpart and other endometrial subtypes.‘

So my name is Felix Blanc-Durand. I’m from Gustave-Roussy France and National University Hospital in Singapore. We have presented this year very intriguing data on clear cell endometrial cancer.

These cancers are a rare subtype of endometrial cancer, and they share multiple clinical and pathological characteristics with clear cell ovarian cancer. Today, we present the molecular profile of these patients comparatively with non-clear cell endometrial cancer and comparatively with clear cell ovarian cancer. And intriguingly, we observed that they present and exhibit very different molecular profiles compared to clear cell ovarian cancer.

They have very few RNA mutations, very few KRAS and PIK3C mutations. However, they have very frequently P53 mutations and high loss of heterozygosity scores. So in conclusion, we initially thought that clear cell endometrial cancer were very close to clear cell ovarian cancer, but based on their molecular profile, I think we have to be very cautious when treating them the same way and including them in the same trials.

So I think based on this result, we should consider them as a distinct entity and maybe design a specific trial for this patient and collaborative work is definitely necessary.

More videos and content from ASCO 2024 on OncoDaily.